Search company, investor...
HealOr company logo


Founded Year



Series C | Alive

Total Raised


Last Raised

$7.5M | 12 yrs ago

About HealOr

HealOr is a biopharmaceutical company committed to the development and commercialization of therapeutics impacting skin cells' properties for the purpose of treating various skin pathologies. HealOr has completed a safety and primary efficacy study of its lead drug HO/03/03 a topical drug for the treatment of diabetic foot ulcers and venous leg ulcers.

Headquarters Location

Ness Ziona Science Park 14 Einstein Street


Missing: HealOr's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: HealOr's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing HealOr

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HealOr is included in 2 Expert Collections, including Diabetes.



1,898 items


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

HealOr Patents

HealOr has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Traumatology, Cell biology, Proteins, Medical treatments


Application Date


Grant Date



Related Topics

Transcription factors, Traumatology, Cell biology, Proteins, Medical treatments



HealOr Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HealOr Rank

HealOr Frequently Asked Questions (FAQ)

  • When was HealOr founded?

    HealOr was founded in 2002.

  • What is HealOr's latest funding round?

    HealOr's latest funding round is Series C.

  • How much did HealOr raise?

    HealOr raised a total of $7.5M.

  • Who are the investors of HealOr?

    Investors of HealOr include Pitango Venture Capital.

  • Who are HealOr's competitors?

    Competitors of HealOr include Elusys Therapeutics, Clarus Therapeutics, VIVUS, BioMarck Pharmaceuticals, Ziopharm Oncology and 8 more.

Compare HealOr to Competitors

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Eurand S.p.A

The company are a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using the company's drug formulation technologies. The company are dedicated to the continued development and commercialization of products that better satisfy patients' needs. The company's research efforts are focused on the development of treatment options with enhanced efficacy, safety and convenient dosing. The company have a pipeline of products in development for ourselves and the company's co-development collaborators.

arGentis Pharmaceuticals

arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

InCode BioPharmaceutics

Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). The company's preclinical results show rapid depletion of C3 without any observed adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin. A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings. The company have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). The company have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH). Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the potent activity of HC3-1496. The company intend to initiate human clinical trials in selected indications within 18 months.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.